Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents

Diabetes Research and Clinical Practice

Volumn 100, Issue 2, 2013, Pages 203-209

  Ludvigsson, Johnny ^a   Carlsson, Annelie ^b   Deli, Ahmed ^c   Forsander, Gun ^b   Ivarsson, Sten A ^e   Kockum, Ingrid ^b   Lindblad, Bengt ^d   Marcus, Claude ^f   Lernmark, Åke ^c   Samuelsson, Ulf ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BMI; C peptide; Children; Intervention trials; Natural course; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; INSULIN ANTIBODY;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; AUTUMN; BODY MASS; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; SYMPTOM;

ADOLESCENT; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 84878376574     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.03.003     Document Type: Article

References (34)

1. Nordwall M., Ludvigsson J. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years. Diabetes Metab Res Rev 2008, 24:472-479.
2. Ludvigsson J., Carlsson A., Forsander G., Ivarsson S., Kockum I., Lernmark A., et al. C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2012, 13:45-50.
3. Palmer J.P. C-peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev 2009, 25:325-328.
4. Palmer J.P., Fleming G.A., Greenbaum C.J., Herold K.C., Jansa L.D., Kolb H., et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004, 53:250-264.
5. Ludvigsson J. C-peptide an adequate endpoint in type 1 diabetes. Diabetes Metab Res Rev 2009, 25:691-693.
6. Madsbad S., Alberti K.G., Binder C., Burrin J.M., Faber O.K., Krarup T., et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J 1979, 2:1257-1259.
7. Komulainen J., Lounamaa R., Knip M., Kaprio E.A., Akerblom H.K. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell function. Childhood Diabetes in Finland Study Group. Arch Dis Child 1996, 75:410-415.
8. Steffes M.W., Sibley S., Jackson M., Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003, 26:832-836.
9. Luppi P., Cifarelli V., Wahren J. C-peptide and long-term complications of diabetes. Pediatr Diabetes 2011, 12:276-292.
10. Wahren J., Ekberg K., Jörnvall H. C-peptide is a bioactive peptide. Diabetologia 2007, 50:503-509.
11. Ludvigsson J., Heding L., Liedén G., Marner B., Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J 1983, 286:176-178.
12. The Canadian-European Randomized Control Trial Group Cyclosporin-induced remission of IDDM after early intervention. Association of 1yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988, 37:1574-1582.
13. Feutren G., Papoz L., Assan R., Vialettes B., Karsenty G., Vexiau P., et al. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986, 2:119-124.
14. Coutant R., Landais P., Rosilio M., Johnsen C., Lahlou N., Chatelain P., et al. Low dose linomide in type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998, 41:1040-1046.
15. Ludvigsson J., Samuelsson U., Ernerudh J., Johansson C., Stenhammar L., Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001, 85:149-154.
16. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
17. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., Mathieu C., Kaufman L., Hale G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005, 352:2598-2608.
18. Pescovitz M.D., Greenbaum C.J., Krause-Steinrauf H., Becker D.J., Gitelman S.E., Goland R., et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009, 361:2143-2152.
19. Mastrandrea L., Yu J., Behrens T., Buchlis J., Albini C., Fourtner S., et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009, 32:1244-1249.
20. Couri C.E., Oliveira M.C., Stracieri A.B., Moraes D.A., Pieroni F., Barros G.M., et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009, 301(15):1573-1579.
21. Ludvigsson J., Faresjö M., Hjorth M., Axelsson S., Chéramy M., Pihl M., et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008, 359:1909-1920.
22. Ludvigsson J., Hjorth M., Cheramy M., Axelsson S., Pihl M., Forsander G., et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011, 54:634-640.
23. Raz I., Elias D., Avron A., Tamir M., Metzger M., Cohen I.R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001, 358:1749-1753.
24. Wherrett D.K., Bundy B., Becker D.J., DiMeglio L.A., Gitelman S.E., Goland R., et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011, 378:319-327.
25. Sherry N., Hagopian W., Ludvigsson J., Jain S.M., Wahlen J., Ferry R.J., et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011, 378:487-497.
26. Ludvigsson J., Krisky D., Casas R., Battelino T., Castano L., Greening J., et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012, 366:433-442.
27. Schloot N.C., Meierhoff G., Lengyel C., Vándorfi G., Takács J., Pánczél P., et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007, 23:276-285.
28. Greenbaum C.J., Beam C.A., Boulware D., Gitelman S.E., Gottlieb P.A., Herold K.C., et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 Diabetes TrialNet data. Diabetes 2012, 61(August (8)):2066-2073. [Epub 2012 June 11].
29. Mayer-Davis E.J., Andrews J.S., Dolan L.M., Pihoker C., Hamman R.F., Greenbaum C., et al. Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth Study. Diabetologia 2012, 55(December (12)):3359-3368. [Epub 2012 September 20]. 10.1007/s00125-012-2719-6.
30. Hanberger L., Samuelsson U., Lindblad B., Ludvigsson J., Swedish Childhood Diabetes Registry SWEDIABKIDS A1C in children and adolescents with diabetes in relation to certain clinical parameters: the Swedish Childhood Diabetes Registry SWEDIABKIDS. Diabetes Care 2008, 31:927-929.
31. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl. 1):S5-S20.
32. The Swedish pediatric diabetes quality register (SWEDIABKIDS); 2010. https://www.ndr.nu/ndr2/.
33. Ludvigsson J., Carlsson A., Forsander G., Ivarsson S., Kockum I., Lernmark A., et al. C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2011, (September). 10.1111/j.1399-5448.2011.00807.
34. Delli A.J., Vaziri-Sani F., Lindblad B., Elding-Larsson H., Carlsson A., et al. ZnT8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis (BDD) study. Diabetes 2012, 61(October (10)):2556-2564.